Included in the formulation
АТХ:R.07.A.A Pulmonary surfactants
R.07.A.A.01 Colfosceryl palmitate
Pharmacodynamics:It has a surfactant-like effect that reduces the surface tension in the alveolar walls.
The clinical effect is manifested by an improvement in the extensibility of the lungs, a reduction in the duration of ventilation and an improvement in gas exchange.
Pharmacokinetics:Not studied.
Indications:Prevention of respiratory distress syndrome: in newborns with a body weight of less than 1350 g; in newborns with a body weight of more than 1350 g with signs of immaturity of the lungs.
Treatment of respiratory distress syndrome in newborns (according to vital indications).
Prevention of barotrauma of the lungs, pneumothorax, interstitial emphysema.
X.J90-J94.J93.9 Pneumothorax, unspecified
X.J90-J94.J93.8 Other pneumothorax
X.J90-J94.J93 Pneumothorax
X.J95-J99.J96 Respiratory failure, not elsewhere classified
X.J95-J99.J98.2 Interstitial emphysema
X.J40-J47.J43.9 Emphysema (lung) (pulmonary)
X.J40-J47.J43.8 Other emphysema
X.J40-J47.J43 Emphysema
XVI.P20-P29.P22.0 Syndrome of respiratory distress in a newborn
XVI.P20-P29.P22 Breathing disorder in a newborn [distress]
Contraindications:Hypersensitivity, pregnancy, lactation.
Pregnancy and lactation:Category FDA not determined.
Contraindicated in pregnancy.For the duration of treatment, breastfeeding should be discontinued.
Dosing and Administration:For prevention and treatment (according to vital indications) of a serious distress syndrome - colfosceril palmitate pediatric in the form of a solution is introduced through the endotracheal tube in a dose of 5 ml (67.5 mg) per 1 kg of body weight. If necessary, repeat the same dose 12 and 24 hours later. The minimum recommended time for the full dose is 4 minutes. The solution is prepared ex tempore (8 ml of sterile water for injection into a vial containing a dry substance is injected with a sterile syringe, the resulting solution is injected into a syringe and reinserted into the vial 3-4 times, shaking and rotating it). The necessary amount of solution is taken at the position of the end of the needle much deeper than the surface of the foam.
Side effects:Pulmonary bleeding (especially with pronounced signs of immaturity of the lungs), an increase in the frequency of apnea. During the introduction: reflux, a drop in percutaneous oxygen saturation> 20%.
Interaction:Not described.
Special instructions:Before the introduction, it is important to make sure that the endotracheal tube is in the trachea (measures must be taken to ensure the patency of the child's airways, the drug can only be administered through the endotracheal tube in conditions artificial ventilation through the lateral opening of the adapter without interrupting mechanical ventilation, during insertion it is necessary that the proximal endotracheal tube is in an upright position), the chest excursion with each mechanical inspiration is uniform and symmetrical, and even breathing noises are heard in both armpits. The full dose should be administered slowly, so that the drug does not accumulate in the endotracheal tube.
Continuous monitoring of ECG, systemic blood pressure and transcutaneous oxygen saturation of blood is necessary: the introduction should be slowed down or stopped if the skin color of the child worsens, heart rate decreases, there is a marked decrease in oxygen concentration in the arterial blood, and also in the case of accumulation of the drug in the endotracheal tube. After the procedure, it is necessary to monitor the medical staff for at least 30 minutes and determine the gas composition of the arterial blood to diagnose possible hypoxia and hypocarbia.
The unused solution is not to be stored.